Breaking Down Neusoft Corporation Financial Health: Key Insights for Investors

Neusoft Corporation's latest results pose a complex picture for investors: Q3 2025 revenue rose to CNY 2.80 billion (+8.13% QoQ) while TTM revenue of CNY 12.16 billion signals an 8.85% YoY gain, yet the company posted a Q3 net loss of CNY -5.19 million contributing to a TTM net loss of CNY -38.23 million and a negative EPS of CNY -0.03; market value sits around CNY 11.73 billion (share price CNY 9.84 as of Dec 11, 2025) with a modest debt-to-equity ratio of 0.12 and cash & short-term investments of CNY 2.12 billion (down 22.55% YoY), while valuation metrics show a trailing P/E of 235.50 but a forward P/E of 24.15 and forecasts call for earnings growth of 71% p.a. and revenue growth of 19.5% p.a.; given compressed margins (Q3 operating margin -1.64%, TTM net margin -0.31%), declining free cash flow (Q2 2025 FCF CNY -246.18 million) and EBITDA volatility (Q3 EBITDA CNY 80.87 million, down 67.11% QoQ), the detailed sections below unpack what these concrete figures mean for risk, valuation and upside-read on for the full analysis.

Neusoft Corporation (600718.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 2.80 billion (up 8.13% vs. previous quarter).
• Trailing twelve months (TTM) revenue: CNY 12.16 billion (up 8.85% YoY).
• Full-year 2024 revenue: CNY 11.56 billion (up 9.64% vs. 2023).
• Revenue per employee: ~CNY 674,800 based on 18,021 employees.
• Price-to-Sales (P/S) ratio: 0.96 (market capitalization equals ~96% of annual sales).
• Market capitalization: CNY 11.73 billion; share price: CNY 9.84 (as of 11 Dec 2025).

• Sales momentum: Q3 sequential growth (8.13%) coupled with ~9% YoY expansion in TTM revenue indicates steady top-line acceleration.
• Operational scale: Revenue per employee (~CNY 674.8k) suggests moderate productivity for a tech/services firm of this size.
• Valuation perspective: P/S of 0.96 implies the market values Neusoft at roughly one year's revenue-neither richly nor deeply discounted relative to sales.

Neusoft Corporation (600718.SS) - Profitability Metrics

Recent quarterly and trailing twelve-month (TTM) results show pressure on Neusoft's profitability, with negative earnings in Q3 2025 and subdued returns on capital. Key figures below quantify the deterioration and signal limited margin cushion.

• Q3 2025 net income: CNY -5.19 million (prior quarter: CNY 68.36 million)
• TTM net income: CNY -38.23 million - TTM EPS: CNY -0.03
• Q3 2025 operating margin: -1.64% (operating loss)
• TTM net profit margin: -0.31%
• Return on Assets (ROA): 0.90%
• Return on Equity (ROE): -0.35%
• Q3 2025 EBITDA: CNY 80.87 million (down 67.11% QoQ)

For additional context on ownership and investor behavior, see Exploring Neusoft Corporation Investor Profile: Who's Buying and Why?

Neusoft Corporation (600718.SS) Debt vs. Equity Structure

As of June 2025, Neusoft Corporation (600718.SS) presents a conservative leverage profile with improvements in liabilities year-over-year and metrics that highlight both strengths and areas to monitor in short-term liquidity.

• Total liabilities: CNY 9.02 billion (down 6.55% YoY).
• Total equity: CNY 9.65 billion, producing a debt-to-equity ratio of 0.12.
• Interest coverage ratio: 9.46 - strong ability to service interest expense.
• Current ratio: 1.26 - sufficient short-term asset coverage of liabilities.
• Quick ratio: 0.61 - potential near-term liquidity pressure without inventory conversion.
• Debt-to-EBITDA: 2.14 - roughly two-plus years of EBITDA to cover outstanding debt.

Key considerations for investors:

• Low debt-to-equity (0.12) supports financial flexibility for growth or defensive actions.
• Interest coverage near 9.5 reduces refinancing or default risk under current earnings.
• Quick ratio of 0.61 signals that operational cash generation or inventory conversion is important to meet very short-term liabilities.
• Debt-to-EBITDA at 2.14 is within a moderate range - manageable but worth monitoring if EBITDA declines.

Contextual background on the company's strategy and evolution can be found here: Neusoft Corporation: History, Ownership, Mission, How It Works & Makes Money

Neusoft Corporation (600718.SS) - Liquidity and Solvency

Key balance-sheet and cash-flow metrics for Neusoft Corporation (600718.SS) as of June 2025 highlight tightening liquidity and mixed solvency trends. Below are the primary figures and short contextual notes.

• Cash & short-term investments: CNY 2.12 billion (-22.55% YoY)
• Total assets: CNY 18.68 billion (-1.50% YoY)
• Total liabilities: CNY 9.02 billion (-6.55% YoY)
• Total equity: CNY 9.65 billion (implied balanced capital structure)
• Net change in cash (Q2 2025): CNY -123.85 million (-110.22% YoY)
• Free cash flow (Q2 2025): CNY -246.18 million (-144.94% YoY)

Interpretation pointers:

• Liquidity: cash buffer down 22.55% to CNY 2.12bn - elevates short-term liquidity risk if negative operating cash flow persists.
• Solvency: assets (CNY 18.68bn) vs liabilities (CNY 9.02bn) yield an equity base of CNY 9.65bn, indicating a roughly 1:1 liabilities-to-equity split and a conservative leverage profile at the headline level.
• Cash-flow trajectory: Q2 negative net cash and free cash flow (-CNY 123.85m and -CNY 246.18m) point to weakening cash generation, requiring monitoring of working capital, capex, and collections.
• Trend risk: continued declines in cash and worsening FCF could force financing actions (debt drawdown, equity, or asset sales) despite the current balanced capital structure.

Further investor context and ownership dynamics are available here: Exploring Neusoft Corporation Investor Profile: Who's Buying and Why?

Neusoft Corporation (600718.SS) - Valuation Analysis

As of July 5, 2025, Neusoft Corporation (600718.SS) displays a mixed valuation profile: exceptionally high trailing earnings multiple, materially lower forward P/E, modest book valuation, and mid-range enterprise multiples. Below are the key metrics and brief context for each.

• Trailing P/E: 235.50 - indicates current market price far exceeds last twelve months' earnings per share, reflecting either very low recent earnings or high growth expectations priced in.
• Forward P/E: 24.15 - suggests analysts expect earnings to expand meaningfully versus trailing results, bringing valuation back toward more typical levels if realized.
• Price-to-Book (P/B): 1.17 - market values the firm at 117% of its book equity, a near-par valuation to net asset base.
• Enterprise Value / EBITDA: 17.08 - a moderate EV/EBITDA implying the company is valued at roughly 17x operating cash earnings before non-cash charges.
• Price-to-Sales (P/S): 0.98 - the market values the company at 98% of its annual revenue, under 1x sales.
• Market Capitalization: CNY 11.94 billion; Enterprise Value: CNY 11.07 billion - implies modest net cash/lease adjustments (market cap slightly above EV).

Key valuation considerations for investors:

• Reconciliation of trailing vs forward P/E - confirm drivers of forecasted earnings improvement (contract wins, margin recovery, divestitures, or one-time gains).
• Compare EV/EBITDA and P/S to sector peers to assess whether 17.08x and ~1x sales are above or below industry norms.
• Balance sheet context - modest gap between market cap and EV suggests limited net debt; verify cash/debt and off-balance exposures.

Further company context and investor activity can be found here: Exploring Neusoft Corporation Investor Profile: Who's Buying and Why?

Neusoft Corporation (600718.SS) - Risk Factors

• Q3 2025 net loss of CNY 5.19 million versus prior-quarter net income of CNY 68.36 million - a rapid swing into quarterly loss.
• TTM net income of CNY -38.23 million, producing a negative EPS of CNY -0.03, indicating the company failed to generate positive annualized earnings.
• Q3 2025 operating margin at -1.64%, showing an operating loss on core activities.
• TTM net profit margin of -0.31%, reflecting a slight loss relative to total revenue over the trailing year.
• Q3 2025 EBITDA of CNY 80.87 million, down 67.11% from the previous quarter - signaling weakening underlying cash profitability.
• Free cash flow in Q2 2025 of CNY -246.18 million, a 144.94% decline year-over-year, pointing to significant cash generation stress.

• Liquidity risk: negative FCF and TTM losses increase reliance on external financing or asset sales to fund operations and growth initiatives.
• Profitability volatility: sharp QoQ EBITDA decline and operating margin in negative territory raise concerns about sustainable margin recovery.
• Shareholder dilution risk: persistent negative EPS may lead management to seek equity financing, diluting existing holders.
• Execution & market risk: any slowdown in the IT services, healthcare IT, or software segments can further depress revenue and margins.
• Interest & macro risk: weaker earnings reduce buffers against rising interest costs or macroeconomic headwinds, exacerbating financial strain.

Neusoft Corporation (600718.SS) Growth Opportunities

• Consensus forward growth: revenue CAGR ~19.5% per annum; earnings growth ~71% per annum; EPS CAGR ~66.9% per annum.
• Primary focus areas: healthcare IT solutions and automotive electronics (ADAS, cockpit/ECU software).
• Strategic posture: investments targeting China's digital transformation across hospitals, telemedicine, smart mobility and connected-car ecosystems.
• Financial posture: maintains a strong cash position and moderate leverage to fund capex and M&A.
• Competitive advantages: extensive R&D capabilities and a nationwide service network enabling scale and faster commercial rollouts.

• Healthcare IT: demand drivers include hospital digitization, EMR upgrades, cloud-based diagnostic platforms and telehealth-markets with multi-year addressable growth.
• Automotive electronics: rising ADAS adoption, vehicle electrification and software-defined vehicles increase TAM for Neusoft's embedded software, testing and integration services.
• Commercial strategy: pursue higher-value contracts, deepen OEM partnerships, and cross-sell cloud and analytics services to existing healthcare and automotive clients.
• Balance-sheet support: the company's cash liquidity and moderate leverage profile allow patient scaling of R&D and selective acquisitions to accelerate market share gains.